EAM
RLAY icon

Exome Asset Management’s Relay Therapeutics RLAY Stock Holding History

Exome Asset Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.77M Buy
+278,302
New +$2.49M 1.43% 32
2025
Q1 		– Sell
-1,083,487
Closed -$4.46M – 78
2024
Q4 		$4.46M Buy
1,083,487
+668,858
+161% +$3.64M 3.35% 6
2024
Q3 		$2.94M Buy
+414,629
New +$3.1M 1.98% 21

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Exome Asset Management's RLAY Position: Q1 2026 in Review

Exome Asset Management opened a new position in Relay Therapeutics (RLAY) in Q1 2026: 278,302 shares worth $2.77M. The stake represents 1.43% of the portfolio and ranks #32 among its holdings. This is a return to the name: Exome Asset Management previously reported a position in RLAY as recently as Q4 2024.

Exome Asset Management first reported a position in RLAY in Q3 2024 and has held it in 3 quarters since. The position peaked at $4.46M in Q4 2024. 242 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Exome Asset Management held 278,302 shares of Relay Therapeutics worth $2.77M as of Q1 2026.
  • Relay Therapeutics was a new Exome Asset Management position in Q1 2026.
  • Relay Therapeutics made up 1.43% of Exome Asset Management's portfolio in Q1 2026, its #32 holding.
  • Exome Asset Management first reported a position in Relay Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • Exome Asset Management's Relay Therapeutics position peaked at $4.46M in Q4 2024.
  • 242 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.